Share on StockTwits

Aratana Therapeutics (NASDAQ:PETX) CEO Peter Steven St unloaded 25,000 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $13.47, for a total transaction of $336,750.00. Following the transaction, the chief executive officer now directly owns 734,394 shares of the company’s stock, valued at approximately $9,892,287. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Aratana Therapeutics (NASDAQ:PETX) traded up 1.56% during mid-day trading on Monday, hitting $14.28. The stock had a trading volume of 285,877 shares. Aratana Therapeutics has a 52 week low of $6.56 and a 52 week high of $29.32. The stock’s 50-day moving average is $13.18 and its 200-day moving average is $17.84. The company’s market cap is $410.6 million.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.35) by $0.01. The company had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.09 million. Aratana Therapeutics’s revenue was up NaN% compared to the same quarter last year. On average, analysts predict that Aratana Therapeutics will post $-1.51 earnings per share for the current fiscal year.

PETX has been the subject of a number of recent research reports. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Aratana Therapeutics in a research note on Wednesday, May 14th. They now have a $22.00 price target on the stock, down previously from $30.00. Separately, analysts at Zacks downgraded shares of Aratana Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Monday, April 14th. They now have a $18.40 price target on the stock. Finally, analysts at Jefferies Group initiated coverage on shares of Aratana Therapeutics in a research note on Monday, March 24th. They set a “buy” rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Aratana Therapeutics presently has an average rating of “Buy” and an average target price of $28.73.

Aratana Therapeutics, Inc is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.